Improving human coronavirus OC43 (HCoV-OC43) research comparability in studies using HCoV-OC43 as a surrogate for SARS-CoV-2

•HCoV-OC43 grows to a higher titer, sooner in human lung fibroblasts (MRC-5) than in human ileocecal adenocarcinoma cells (HRT-18).•Optimization of an HCoV-OC43 antibody-based TCID50 assay reduced cost by 67 % and time by two hours.•At peak titer the defective virion to infectious virus ratio was...

Full description

Saved in:
Bibliographic Details
Published in:Journal of virological methods 2022-01, Vol.299, p.114317-114317, Article 114317
Main Authors: Schirtzinger, Erin E., Kim, Yunjeong, Davis, A. Sally
Format: Article
Language:English
Subjects:
Chlorocebus aethiops
Coronavirus
Coronavirus OC43, Human
COVID-19
Flow virometry
HCoV-OC43
Humans
Reproducibility of Results
SARS-CoV-2
Virus titration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•HCoV-OC43 grows to a higher titer, sooner in human lung fibroblasts (MRC-5) than in human ileocecal adenocarcinoma cells (HRT-18).•Optimization of an HCoV-OC43 antibody-based TCID50 assay reduced cost by 67 % and time by two hours.•At peak titer the defective virion to infectious virus ratio was
ISSN:0166-0934
1879-0984
DOI:10.1016/j.jviromet.2021.114317